Date of announcement: 2021/08/20

Time of announcement: 16:18:23

Subject: The Company's 2021 annual general meeting approved removal of the noncompetition restrictions for directors

Date of events: 2021/08/20

To which item it meets: paragraph 21

Statement

1. Date of the shareholders' meeting resolution:2021/08/20
2. Name and title of the managerial officer with permission to engage in competitive conduct:Director, TTY Biopharm Co., Ltd.
3. Items of competitive conduct in which the officer is permitted to engage:The business scope is the same as or similar to the Company's.
4. Period of permission to engage in the competitive conduct:For the duration of serving as a director of the Company.
5. Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act):
   (1)A total of 23,215,060 voting rights were represented at the time of voting.
   (2)23,144,863 votes in favor, 99.69% of the total represented voting rights present.
   (3)30,555 votes against, 0.13% of the total represented voting rights present.
   (4)0 invalid vote, 0.00% of the total represented voting rights present.
   (5)39,642 votes abstained and not voted, 0.17% of the total represented voting rights present.
   (6)The number of for votes exceeded the statutory threshold, and the proposal was passed.
6. If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter “N/A” below):N/A
7. Company name of the mainland China enterprise and the officer’s position in the enterprise:N/A
8. Address of the mainland China enterprise:N/A
9. Operations of the mainland China enterprise:N/A
10. Impact on the company’s finance and business:No negative impact.
11. If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio:N/A
12. Any other matters that need to be specified:None.